Please login to the form below

Not currently logged in
Email:
Password:

GSK launches first-in-class epilepsy drug

GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures

GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the adjunct treatment of adults with partial-onset seizures, and demonstrated significant effects in a treatment resistant patient population.

Retigabine is the first AED to target neuronal potassium channels, which are involved in inhibitory mechanisms in the brain. Inhibitory mechanisms are thought to have a role in seizure control.

Professor Martin J Brodie, director of the epilepsy unit at Western Infirmary, Glasgow, UK, said: "Trobalt represents a positive addition to the therapeutic armamentarium for the many adult patients with inadequately-controlled focal onset seizures."

The efficacy and safety of retigabine was established in two pivotal multicentre, randomised, double-blind, placebo-controlled, fixed dose studies where patients who were treatment resistant were recruited. Retigabine significantly improved seizure control, with a greater number of patients achieving a reduction in the number of seizures by 50 per or more, compared with placebo.

Retigabine, referred to as ezogabine in the US, is being jointly developed by GSK and Valeant.

17th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics